Abstract
The early promise of boron neutron capture therapy as a method for the treatment of cancer has been inhibited by the inherent toxicity associated with therapeutically useful doses of 10B-containing pharmacophores, the need for target-tissue specificity and the challenges imposed by biological barriers. Although developments in the synthetic chemistry of polyhedral boranes have addressed issues of toxicity to a considerable extent, the optimisation of the transport and the delivery of boronated agents to the site of action – the subject of this review – is a challenge that is addressed by the development of innovative formulation strategies.
Original language | English |
---|---|
Pages (from-to) | 153-159 |
Number of pages | 7 |
Journal | Drug Discovery Today |
Volume | 17 |
Issue number | 3-4 |
DOIs | |
Publication status | Published - Feb 2012 |